-50%

est. 2Y upside i

Healthcare

Software for pharmacies to move beyond dispensing

Rank

#528

Sector

Healthtech, Pharmacy Software

Est. Liquidity

~3Y

Data Quality

Data: Medium

MedMe Health presents a moderate upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (25%)+300%

MedMe Health's aggressive US expansion and successful adoption of AI-powered tools like Clinical Assistant and Patient Concierge drive revenue to $40M+ by 2028, achieving a $480M valuation (4x current) as it becomes a dominant platform for pharmacy clinical services, attracting a strategic acquisition.

Base (50%)+98%

MedMe Health maintains its strong position in Canada and achieves moderate US market penetration, growing revenue to $28M by 2028 and reaching a $240M valuation (2x current) through consistent execution and product enhancements.

Bear (25%)-40%

Aggressive moves by incumbents like McKesson and Oracle Cerner into clinical services, coupled with slower-than-expected US market traction, limit MedMe Health's growth to $18M revenue by 2028, resulting in a down round to a $70M valuation, significantly impacting common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

low

Investors hold $4M in liquidation preferences ahead of common stock on an estimated $120M valuation.

Dilution Risk

moderate

Further equity funding rounds are likely needed for significant US expansion and AI development, which will result in additional dilution.

Secondary Liquidity

none

Given the company's stage and private status, there is currently no active secondary market for shares.

Questions to Ask at the Interview

Strategic questions based on MedMe Health's data — designed to show you've done your homework.

  • 1

    “Given the strong competitive landscape with incumbents like McKesson and Oracle Cerner expanding into clinical services and telepharmacy, how does MedMe Health plan to sustain its competitive moat and differentiate its AI-powered solutions in the US market?”

  • 2

    “With $14M in revenue and ambitious US expansion plans, what is the projected revenue growth rate for the next 2-3 years, and what key milestones are critical to achieving a successful Series C or acquisition?”

  • 3

    “Considering the recent debt financing and the need for continued investment in US expansion and AI, how does the company envision the timeline for a liquidity event for employees, and what are the plans for managing potential future dilution?”

Community

Valuation Sentiment

Our model estimates -50% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.